Category: Clinical Sciences/Health Conditions
Spasticity is a common symptom for cerebral palsy (CP) patients. AbobotulinumtoxinA is approved for patients (≥2 years) with pediatric lower limb spasticity (PLLS). Quality of life (QoL) and treatment satisfaction are important patient-reported outcomes for patients with PLLS. The objective of this study is to measure QoL outcomes using Pediatric QoL Inventory (PedsQL™) and PedsQL CP from a phase IV study of abobotulinumtoxinA in patients with PLLS.
Patients (aged 2-17 years) treated with abobotulinumtoxinA for PLLS and their caregivers completed PedsQL and PedsQL CP (CP patients only) questionnaires at study inclusion, subsequent injections, and end-of-study visits. PedsQL (23-items) comprises Physical, Emotional, Social, and School Functioning. PedsQL CP (35-items) comprises Daily Activities, School, Movement/Balance, Pain/Hurt, Fatigue, Eating Activities, and Speech/Communication. Items are scored, then transformed to a 0-100 scale (higher scores indicate better QoL).
AbobotulinumtoxinA showed greatest improvements in physical health and school functioning in patients with PLLS as measured by PedsQL. Improvements in daily activities were greatest as measured by PedsQL CP. Safety data will be presented at next interim analysis.
Sarah Evans– Chief, Rehabilitation Medicine, Children’s Hospital of Philadelphia
Mark Gormley– Section Chief, Pediatric Physical Medicine and Rehabilitation, Gillette Children’s Specialty Healthcare
Mauricio Delgado– Professor, University of Texas Southwestern Medical Center and Texas Scottish Rite Hospital for Children
Ann Tilton– Professor of Clinical Neurology Chief, Section of Child Neurology, LSUHSC and Children's Hospital New Orleans
Asare Christian– Associate Director, Outpatient Clinic, Good Shepherd Rehabilitation Hospital
Edward Dabrowski– Associate Professor, Oakland University School of Medicine & Beaumont Hospital
Pascal Maisonobe– Director of Biometrics, Ipsen Bioscience
Stefan Wietek– Director Medical Affairs, Neurology, Ipsen Bioscience
Bruce Rubin– Senior Director, Head of Medical Affairs, Neurology, Ipsen Bioscience